CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that increases plasma levels of growth hormone and insulin-like growth factor 1 (IGF-1). It consists of the first 29 amino acids of GHRH and has been modified to improve stability and potency. The addition of DAC (Drug Affinity Complex) prolongs the plasma half-life of CJC-1295, allowing for sustained growth hormone release over an extended period. Research has shown that CJC-1295 with DAC can produce elevated GH and IGF-1 levels for up to a week following a single administration, making it a subject of significant interest in growth hormone research.